Gearing up for a springtime FDA submission, Sunovion Pharmaceuticals reported today that its apomorphine sublingual film succeeded in a pivotal Phase III trial in patients with Parkinson’s disease who experience motor fluctuations.
Without revealing the study’s full results, the Marlborough, Mass.-based company said that the trial met its primary and key secondary endpoints and that the drug was generally well-tolerated by patients.
Get the full story at our sister site, Drug Delivery Business News.
The post Sunovion touts pivotal Ph3 trial for Parkinson’s drug appeared first on MassDevice.
from MassDevice http://ift.tt/2EoLFqM
Cap comentari:
Publica un comentari a l'entrada